Roivant Sciences (ROIV) Financials

Roivant Sciences (NASDAQ: ROIV) has undergone a major turnaround over the last four years, but the story is still mixed. The company has moved from deep losses and very large cash swings in 2023 to much stronger reported profits in early 2025. However, a large part of the recent earnings strength appears to be driven by special items and investment income rather than core operating profitability.

Revenue remains minimal. In the latest quarter (Q4 2025), ROIV reported just $2.5 million in revenue, up slightly from $2.0 million in the prior quarter and still far below typical levels needed to support the company’s operating cost base. For a biotech/platform company, this is not unusual, but it means investors are still relying heavily on pipeline value and non-operating income.

Margins and operating income improved sharply in the latest quarter, but the quality of that improvement looks questionable. Q4 2025 operating income was $415.2 million, a dramatic swing from a $339.2 million operating loss in Q3 2025. But the quarter also included a very large “Other Special Charges / (Income)” benefit of $770.2 million, which suggests the headline operating result may not be sustainable from ordinary business activity.

Net income rebounded strongly in Q4 2025. The company posted $355.7 million in net income versus a $313.7 million loss in Q3 2025. On a common-shareholder basis, ROIV earned $303.0 million in Q4 2025, or $0.45 basic EPS.

Cash flow remains a key concern. Despite the accounting profit in Q4 2025, operating cash flow was negative $163.8 million. That means the company is still burning cash in its core operations even while reporting income on the bottom line.

Balance sheet liquidity is still strong, but it has come down meaningfully from a year ago. As of Q3 2025, ROIV held $1.48 billion in cash and equivalents plus $3.05 billion in short-term investments, for a very large liquidity cushion. But that is down from $1.99 billion in cash and $3.16 billion in short-term investments at Q3 2024, and the company’s cash balance has been volatile quarter to quarter.

Equity remains substantial. Total equity and noncontrolling interests were $4.97 billion at Q3 2025, compared with $5.58 billion at Q2 2024 and $1.43 billion at Q3 2022. The balance sheet still looks resilient, which is important for a company with negative operating cash flow.

• Large liquidity cushion: ROIV continues to hold billions in cash and short-term investments, giving it flexibility to fund development and transactions.
• Strong Q4 2025 reported profit: Net income of $355.7 million marked a sharp improvement from the prior quarter’s loss.
• Interest and investment income supported results: Q4 2025 included $26.3 million of interest and investment income, helping offset operating weakness.
• Balance sheet remains sizable: Total equity and noncontrolling interests of nearly $5.0 billion provides a substantial capital base.
• Revenue remains immaterial: Quarterly revenue is still only around $2 million to $3 million, so the investment case is not about product sales today.
• Earnings are heavily affected by special items: Large “other special charges / (income)” swings make reported earnings less predictable.
• Share count has stayed fairly elevated: Weighted average diluted shares were about 694 million in Q4 2025, limiting per-share upside.
• Core operations are still cash consuming: Operating cash flow was negative $163.8 million in Q4 2025.
• SG&A and R&D remain high: Combined operating expenses were very large relative to revenue, reflecting the company’s development-stage profile and ongoing cost burden.
• Recent profits may not be durable: The latest quarter’s operating profit appears inflated by one-time items, so investors should be cautious about extrapolating it forward.

Bottom line: Roivant has improved dramatically from its prior losses, and the balance sheet still gives it time. But the business is not yet showing consistent, revenue-driven profitability. For investors, the key question is whether the company can convert its pipeline and investments into recurring operating success rather than relying on volatile special gains and investment income.